Table 1.

Baseline characteristics of the study population stratified by participation in Collaborative Pharmacist Support Services.

	CPSS group n = 359		No-CPSS group n = 999
	n	Mean ± SD or %	n	Mean ± SD or %	P value
Characteristics
Age, y	359	61.5 ± 12.0	999	61.0 ± 12.9	.50
Female sex, %	165	50.8	504	51.7	.90
Race/ethnicity, %					.78
White	306	94.2	910	92.4
Black	2	0.6	9	0.9
Asian	5	1.5	23	2.3
Other/unknown	12	3.7	43	4.4
Insurance product, %					.43
Commercial	167	51.4	535	54.3
Medicare (FFS)	79	24.3	239	24.3
Medicare Advantage	61	18.8	166	16.9
Medicaid	4	1.3	20	2.0
Self-pay/unknown	14	4.3	25	2.6
Health indicators
Smoking status, %					.13
Current	25	6.6	96	9.6
Not current	334	93.4	903	90.4
Clinical characteristics
High blood pressure
Prevalence, %	337	93.9	911	91.2	.78
Duration, y	337	8.2 ± 5.7	911	7.6 ± 5.2	.11
Diabetes mellitus
Prevalence, %	266	74.1	754	75.5	.99
Duration, y	266	6.9 ± 5.1	754	6.1 ± 4.6	.15
Depression, %	151	46.5	439	44.6	.55
Medication class, %
Anti-hypertensive	334	93.0	658	65.9	< .001
Metformin	222	61.8	365	36.5	< .001
Other DM medications*	248	69.1	342	34.2	< .001
Statins	251	77.2	774	78.6	.61
Body mass index, kg/m2	325	34.6 ± 7.6	985	34.5 ± 7.8	.90
Body mass index classes, %
Underweight	1	0.3	3	0.3	.99
Normal	25	7.7	71	7.2
Overweight	69	21.2	213	21.6
Obese	230	70.8	698	70.9
Mean hemoglobin A1c values within 12 months of enrollment, %	266	8.7 ± 2.1	754	7.4 ± 1.8	< .001
Mean blood pressure within 12 months of enrollment
Systolic, mm Hg	337	138.3 ± 18.4	911	129.2 ± 15.3	< .001
Diastolic, mm Hg	337	78.1 ± 12.0	911	76.6 ± 10.3	.05

^*Other diabetes medications included injectable and oral medications excluding metformin.